Despite massive efforts in drug discovery fueled by combinatory chemistry, recombinant DNA technology, and highthroughput screening, surprisingly few molecules make it through the drug development process. While the reasons are debated, it is certain that many new chemical entities (NCEs) suffer from recurring problems that hinder development— low water solubility, instability, or inadequate pharmacokinetics. An estimated 43% of NCEs are poorly water-soluble. An entire conference, the 44th Annual Pharmaceutical Research and Development Conference, was devoted to the theme of strategies for formulating poorly water-soluble drugs
